AGIOHealthcare · BiotechnologyThe 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. hold a median 12-month price target of $45 — +39.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Agios Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (87): Analysts have, on balance, been raising their forecasts.
Volatility (39): The share price moves around a lot.
Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AGIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.4% from it.
Of the 20 most recent actions, 7 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Sept 2026 | B of A Securities | Maintains | Buy | $46 → $50 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $31 → $34 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 31 July 2026 | Citigroup | Maintains | Buy | — |
| 31 July 2026 | Citigroup | Maintains | Buy | $46 → $52 |
| 31 July 2026 | Truist Securities | Maintains | Buy | $41 → $39 |
| 31 July 2026 | Truist Securities | Maintains | Buy | — |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $52 → $55 |
| 21 July 2026 | HC Wainwright & Co. | Maintains | Buy | $54 → $52 |
| 21 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 July 2026 | B of A Securities | Maintains | Buy | — |
| 7 July 2026 | B of A Securities | Maintains | Buy | $40 → $46 |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $28 → $32 |
| 7 July 2026 | Truist Securities | Maintains | Buy | $36 → $41 |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2026 | JP Morgan | Maintains | Neutral | — |
| 29 May 2026 | B of A Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGIO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Agios Pharmaceuticals, Inc. returned −25.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 9% of US stocks
Cheaper than 47% of US stocks
Cheaper than 75% of US stocks
Higher than 96% of US stocks
Higher than 92% of US stocks
Higher than 98% of US stocks
Higher than 10% of US stocks
Higher than 99% of US stocks
Higher than 26% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Agios Pharmaceuticals, Inc. has a market value of $1.9B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $98.3M. The latest quarter grew 259.3% year on year.
Net income over the same four quarters: −$411.3M, a −418.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$390.3M.
Trailing P/E: 3.8×; forward P/E: −8.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Agios Pharmaceuticals, Inc. employs 539 people — $182K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Agios Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Agios Pharmaceuticals announced it will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET, to discuss its third-quarter 2026 financial results.
Why it matters — The event provides AGIO watchers with a scheduled opportunity to hear the company’s third-quarter financial results.
Agios faces a narrower growth path after setbacks for tebapivat, shifting attention to mitapivat sales, SCD expansion and regulatory prospects. The headline reports AGIO stock sank 29% in three months.
Why it matters — The setbacks and resulting focus on other products and prospects shape the company’s growth outlook for AGIO watchers.
According to Zacks Investment Research, Agios Pharmaceuticals' growth story is increasingly tied to mitapivat's commercial expansion, with its drug Aqvesme gaining traction. Meanwhile, a sickle cell disease (SCD) opportunity and pipeline setbacks are heightening mitapivat's importance to the company.
Why it matters — AGIO watchers would care because mitapivat's commercial performance is emerging as the central driver of the company's growth, especially given the added weight of pipeline setbacks and the SCD opportunity.
Agios Pharmaceuticals is expanding mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease. The thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% year-over-year, with strong payer coverage and operational leverage emerging. The company's $965M cash position supports pipeline expansion ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.
Why it matters — AGIO watchers would care because mitapivat's revenue growth, expanding indications, and cash position point to a strengthening rare-disease franchise ahead of a key sickle cell PDUFA decision.
Agios Pharmaceuticals reported second-quarter revenue and earnings that surpassed analyst estimates, driven by sales of Pyrukynd and the launch of Aqvesme, while continuing to advance its hematology pipeline.
Why it matters — An AGIO watcher would care because the company demonstrated financial momentum with its newer product launches and pipeline development, reinforcing its commercial execution in the hematology space.
The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. have a median 12-month price target of $45, with estimates ranging from $32 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Agios Pharmaceuticals, Inc., 7 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agios Pharmaceuticals, Inc. 81 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Agios Pharmaceuticals, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +39.4% from the last close, and Ticker Nerd's factor model ranks Agios Pharmaceuticals, Inc. 81 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Agios Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $73 over the next 12 months.
Agios Pharmaceuticals, Inc. returned -25.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET". Agios Pharmaceuticals announced it will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET, to discuss its third-quarter 2026 financial results.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
CEO Mr. Brian M. Goff M.B.A. · 539 employees · United States · https://www.agios.com
